Molecular Medicine Reports Molecular Medicine Reports 1791-2997 1791-3004 D.A. Spandidos 10.3892/mmr.2013.1567 mmr-08-03-0853 Articles Lack of effect of common single nucleotide polymorphisms in leukotriene pathway genes on platelet reactivity in patients with diabetes ROSIAKMAREK1* POSTULAMAREK2* KAPLON-CIESLICKAAGNIESZKA1 KONDRACKAAGNIESZKA3 TRZEPLAEWA1 ZAREMBAMALGORZATA2 FILIPIAKKRZYSZTOF J.1 KOSIORDARIUSZ A.4 CZLONKOWSKIANDRZEJ2 OPOLSKIGRZEGORZ1 JANICKIPIOTR K.5 Department of Cardiology, Medical University of Warsaw, Warsaw 02-927, Poland Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw 02-927, Poland Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw 02-927, Poland Department of Noninvasive Cardiology and Hypertension, Central Clinical Hospital, The Ministry of the Interior, Warsaw 02-507, Poland Perioperative Genomics Laboratory, Department of Anesthesiology, Penn State College of Medicine, Hershey, Pennsylvania 17033-0850, USA Correspondence to: Dr Marek Postula, Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, 26/28 Krakowskie Przedmiescie, Warsaw 02-927, Poland, E-mail: mpostula@wum.edu.pl

Contributed equally

 9 2013 03 07 2013 8 3 853 860 01 01 2013 17 06 2013 Copyright © 2013, Spandidos Publications 2013 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.

The aim of the present study was to investigate the effect of genetic polymorphisms in candidate genes within the leukotriene (LT) pathway on platelet reactivity and the concentration of selected LTs in diabetic patients treated with acetylsalicylic acid (ASA). The study cohort consisted of 287 Caucasians with type 2 diabetes who had received treatment with ASA tablets (75 mg/day) for at least three months. Platelet reactivity analyses were performed using VerifyNow aspirin and PFA-100 assays. The measured LTs included leukotriene B4 (LTB4) and leukotriene E4 (LTE4). Genotyping for the selected 25 single nucleotide polymorphisms (SNPs) within six genes of the LT pathway was performed using a Sequenom iPLEX platform. No statistically significant association was observed between the investigated SNP genotypes, platelet reactivity and measured LTs in the patient cohort. The results of our study suggest that certain polymorphisms of the LT pathway are not associated with altered platelet reactivity and the measured LTs in diabetic patients treated with ASA.

 acetylsalicylic acid leukotrienes diabetes mellitus single nucleotide polymorphisms platelet reactivity Introduction

Acetylsalicylic acid (ASA) is an effective inhibitor of platelet thromboxane A2 (TxA2) synthesis by cyclooxygenase-1 (COX-1), nevertheless it is often considered a relatively weak platelet inhibitor due to its limited effect on aggregation in the presence of high concentrations of other agonists, such as adenosine-5′-diphosphate (ADP) or collagen (1–3).

ASA-induced COX-1 inhibition may cause alternative processing of arachidonic acid (AA) via the 5-lipoxygenase (5-LOX) pathway, resulting in the increased production of proinflammatory leukotrienes (LTs) (4). In leukocytes, the 5-lipoxygenase gene (ALOX5) and the 5-lipoxygenase-activating protein gene (ALOX5AP) initialize the biosynthesis of LTs from AA. The biologically active LTs are synthesized by subsequent conversion to LTB4 and the cysteinyl LTs (LTC4, LTD4 and LTE4) via enzymatic reactions with LTA4 hydrolase (LTA4H) and LTC4 synthase (LTC4S), respectively (Fig. 1) (5). LTs subsequently affect the function of the target cells, including monocytes and other pro-inflammatory leukocytes, through receptor-mediated signal transduction.

The majority of research on the association of genomics and platelet reactivity with ASA therapy has been focused on specific agonists or single pathway platelet function phenotypes (6). Several single nucleotide polymorphisms (SNPs) may be responsible for certain inter-individual differences in platelet reactivity in the type 2 diabetes mellitus (T2DM) population treated with ASA (7).

The aim of this study was to determine whether SNPs in candidate genes, including ALOX5, ALOX5AP, ALOX12, ALOX15, LTA4H and LTC4S, in Caucasian patients with T2DM are associated with changes in platelet function analyzer (PFA)-100 collagen/epinephrine closure time (CEPI-CT) and/or collagen/ADP closure time (CADP-CT) and/or VerifyNow aspirin reaction units (ARU) and the concentrations of LTB4 and LTE4.

 Materials and methods Patient population and study design

The local ethics committee of the Medical University of Warsaw approved the study protocol and the informed consent form (date of approval, May 29 2007; certification number, KB/77/2007). The study was conducted in accordance with the Declaration of Helsinki and informed written consent was obtained from all patients. The genotyping in this study was reviewed and approved by the Institutional Review Board of Penn State Hershey Medical Center (Hershey, PA, USA). The subjects of the study were recruited consecutively from patients with T2DM participating in a multi-center, prospective, randomized and open-label AVOCADO (aspirin vs./or clopidogrel in aspirin-resistant diabetics inflammation outcomes) study presenting to the outpatient clinic of the Central Teaching Hospital of the Medical University of Warsaw. The full characterization of the population of the study, including the inclusion and exclusion criteria, have been published previously (7). Caucasian subjects with T2DM who, at the time of enrollment, had been receiving treatment with ASA tablets (75 mg/day) for at least 3 months for the primary or secondary prevention of myocardial infarction (MI) were recruited. No clopidogrel or antiplatelet drugs other than ASA were used in any of the investigated patients. All patients had received oral antidiabetic agents and/or insulin for at least 6 months; diet-controlled diabetic patients were not included in the study. Compliance to ASA therapy was determined upon enrollment in the study based on the statement of the patient and measurement of S-TxB2 levels.

 Blood sample and assay procedure

Blood samples were obtained in the morning 2–3 h following the previous dose of ASA. Blood was extracted from the antecubital vein and the initial 2 ml of blood was discarded in order to avoid spontaneous platelet activation. Blood was drawn into tubes containing 3.2% sodium citrate for VerifyNow measurements and 3.8% sodium citrate for PFA-100 measurements. Blood samples were processed within 2 h of collection. For S-TxB2, whole blood was allowed to clot at 37°C for 1 h prior to serum separation by centrifugation. Serum was obtained from venous blood by centrifugation at 1000 × g for 15 min at 4°C and aliquots were stored at −80°C for further analysis. Routine laboratory testing was performed at the laboratory of the Central Teaching Hospital of the Medical University of Warsaw using standard techniques, including complete blood cell and platelet counts, fasting glycemia, glycosylated hemoglobin (HbA1c), lipid profile, C-reactive protein and serum creatinine concentrations.

The concentration of the functional epitope of the vWF molecule (vWF:Ag) was measured in the citrate plasma samples using an enzyme immunoassay (EIA) kit according to the manufacturer’s instructions (vWF Activity Kit, Sekisui Diagnostics, Stamford, CT, USA).

S-TxB2 and serum LTB4 concentrations were also measured with an EIA kit according to the manufacturer’s instructions (EIA kits, Cayman Chemicals, Ann Arbor, MI, USA). Each set of TxB2 and LTB4 EIA kits were tested for the impact of interferences. The correlation of results in three dilutions of five random samples were assessed, as proposed by the manufacturer’s instructions within the kit. Following the analysis of results, it was decided that the assay was to be used without purification, as the differences between the results did not exceed 20%. Samples with results outside the standard curve were re-assayed with appropriate dilutions. Optimal compliance was confirmed by S-TxB2 levels <7.2 ng/ml in all patients, as described previously in a diabetic population by Mortensen et al(1).

The first morning urine sample was collected and delivered by the patient within 2 h. The samples were collected into tubes containing indomethacin and subsequently stored at −80°C for further analysis. Urinary LTE4 concentrations were measured using an EIA kit according to the manufacturer’s instructions (Cayman Chemicals), following extraction and purification on SPE (C18) columns (Waters Associates, Milford, MA, USA), and data were normalized for urinary creatinine concentration.

 Platelet function analysis VerifyNow

The VerifyNow aspirin assay (Accumetrics, San Diego, CA, USA) uses cartridges containing a lyophilized preparation of human fibrinogen-coated beads and AA. The assay is a turbidimetric-based optical detection system, which measures platelet-induced agglutination as the increase in light transmittance in response to AA and converts luminosity transmittance units into ARU for VerifyNow. According to the manufacturer, ARU ≥550 indicates no effect of ASA on platelet aggregation, whereas ARU <550 indicates platelet dysfunction due to inhibition of the COX-1-dependent pathway (8).

 PFA-100

The PFA-100 assay (Dade-Behring International, Inc., Newark, DE, USA) uses whole blood and simulates high shear stress conditions. A syringe aspirates citrated whole blood at a high shear rate through a small aperture cut into a membrane, coated with 2 μg of type I collagen and either 10 μg epinephrine (EPI) bitartrate or 50 μg ADP. The instrument records the time required for occlusion of the aperture, defined as CT, which is indicative of platelet reactivity in the whole blood sample. Based on our own and other previous reports (7,9–11), we applied three different cut-off values for high platelet reactivity in the CEPI-CT assay. In the first approach, adequate platelet inhibition with ASA is defined as CEPI-CT ≥165 sec, and in the second as CEPI-CT ≥193 sec (the manufacturer’s lower limit of the normal range for aspirin-free healthy controls) (12). The maximum CT provided for PFA-100 is 300 sec and is equivalent to non-occlusion (13). Thus, patients with CEPI-CT values ≥300 sec were defined as an alternative population with adequate platelet inhibition (14). Cut-off values for CADP-CT were based on the median value in the studied population.

 DNA extraction, quality control and quantification

DNA was obtained from whole blood samples and frozen until it was required for analysis, which employed the membrane ultrafiltration method using a Fuji MiniGene 80 extractor (FujiFilm Life Sciences distributed by AutoGen, Inc., Holliston, MA, USA). DNA concentrations were determined spectrofluorometrically using a PicoGreen dsDNA Quantitation Reagent kit (Molecular Probes Inc., Eugene, OR, USA).

 Individual SNP genotyping

Genotyping was performed at the Boston Children’s Hospital (Boston, MA, USA) using a custom Sequenom iPLEX assay in conjunction with the MassARRAY platform (Sequenom Inc., San Diego, CA, USA). One panel of SNP markers was designed using Sequenom Assay Design 3.2 software.

 Statistical analysis of results Power analysis

We planned a prospective, observational study of diabetic patients treated with ASA. The Hardy-Weinberg equilibrium (HWE) was evaluated using the two-tailed Chi-square test. The primary analysis utilized the two-tailed Chi-square test followed by univariate logistic regression with genotypes for each SNP as dependent variables, and VerifyNow ARU >550 phenotype (high on ASA platelet reactivity) as a binary independent variable. The logistic regression procedure enabled us to estimate the log of the odds ratio (OR), a measure of the increase in odds of experiencing VerifyNow ARU >550 for subjects carrying the variant compared with wild-type subjects. We obtained a 95% confidence interval around this estimate and the P-value for the OR. The P-value was compared with the pre-defined cut-off for statistical significance (α = 0.05/number of investigated SNPs and outcome phenotypes = 0.0017, since the nominal α-level of 0.05 was corrected by the Bonferroni method for 25 simultaneously analyzed polymorphisms and five outcome phenotypes). Given the expected population incidence of VerifyNow ARU>550 in the investigated diabetic population of ~20%, average allele frequency of minor allele 0.2, alpha level=0.0017 and a statistical power of 0.8, the study required at least 280 subjects to detect clinically significant OR=3 for experiencing VerifyNow ARU>550 in carriers of the minor allele.

Initial power analysis revealed that none of the analyzed SNP genotypes were associated with any of the measured outcome phenotypes (platelet reactivity or LTs concentrations).

 Statistical calculations

Statistical analyses were performed using IBM-SPSS ver. 19 and Stata (Stata Corporation, College Station, TX, USA) software. Deviations from the HWE were calculated using the Chi-square test. The recorded clinical data, when distributed normally in the analyzed group of patients, are presented as the mean ± SD, and non-normally distributed data are presented as median and the interquartile range (IQR). We compared the distribution of predefined cut-off values for the assays, CEPI-CT for PFA-100 (<165 sec, <193 sec and <300 sec) and the ARU for VerifyNow (<550) using exact Chi-square statistics and distribution of medians, CEPI-CT and CADP-CT for PFA-100 and ARU for VerifyNow among all genotypes of successfully genotyped SNPs for three genotypes (homozygotes for minor allele and heterozygotes and homozygotes for major allele) using the Kruskal-Wallis test. SNPs were considered to be statistically significant when P<0.05/30 (the P-value is corrected for multiple comparisons).

SNPs with nominal statistically significant (P<0.05 prior to correcting for multiple comparisons) differences in the measurements for AA metabolite concentrations (LTE4 and LTB4) between medians for three genotypes (homozygotes for minor allele, heterozygotes and homozygotes for major allele) were subjected to further testing based on the dominant, recessive or additive genetic model by the Mann-Whitney test.

 Results Patients

From the initially enrolled 304 patients, complete clinical data and blood samples were available for 298 patients. Subsequently, eight patients were eliminated from the analysis due to suspected ASA non-compliance (S-TxB2 concentrations >7.2 ng/ml) and a further three patients were eliminated due to the lack of corresponding biochemical and genotype data. Demographic characteristics, clinical data and the results of platelet reactivity measurements, serum concentrations of S-TxB2, LTB4 and urinary concentrations of LTE4 for the remaining 287 patients are summarized in Table I.

 Genotyping

Genotyping was initially attempted for 25 selected SNPs (see Fig. 1) in all 287 patients. There was one SNP that was considered to be a failure as it genotyped poorly (cut-off <85%; rs2660880, LTA4H gene) and one SNP was not included in the final analysis as we observed only homozygotes in our population (rs62406223, LTC4S gene). The remaining 23 SNPs genotyped well (>86% success rate) and were in the HWE.

The results of the allele and genotype frequencies for all genotyped SNPs included in the final analysis are summarized in Table II. For each of the successfully genotyped SNPs, we compared the corresponding platelet reactivity measurements (CEPI-CT and CADP-CT for PFA-100 and ARU for VerifyNow), serum LTB4 concentrations and urine concentrations of LTE4 data between three allelic groups (homozygotes for minor and major alleles, in addition to heterozygotes) using the non-parametric Kruskal-Wallis test. We observed no statistically significant differences in the platelet reactivity measurements and LTB4 or LTE4 concentrations for carriers and non-carriers of the investigated SNP variants (Table III). We did not observe any statistically significant results for groups of patients based on predefined cut-off values for platelet reactivity assays (CEPI-CT and ARU; data not shown).

 Discussion

We genotyped 24 common SNPs within six genes associated with the metabolism of AA to LTs; six SNPs in ALOX5AP, three SNPs in ALOX5, three SNPs in ALOX12, two SNPs in ALOX15, one SNP in LTC4S and nine SNPs in LTAH4. In our study, no correlation was observed between the SNPs in candidate genes and measured platelet reactivity or metabolites of the LT pathway (LTB4 or LTE4) in a population of patients with T2DM. These findings suggest that no major effects of these genetic variations on inter-individual variations in platelet reactivity or LT pathway metabolites occur in the T2DM population.

The lack of correlation between SNPs within the LT metabolism pathway observed in our study does not exclude the role of the LT pathway metabolites in the pathogenesis of thrombosis. LTs posses an established role in a wide variety of inflammatory diseases, including asthma, allergic rhinitis, atherosclerotic cardiovascular disease (CVD), inflammatory bowel disease, multiple sclerosis and cancer (15–21). Moreover, Camacho et al(22) observed a significant genetic correlation between the expression of ALOX5AP and LTA4H and arterial thrombosis. The correlation between LTA4H and arterial thrombosis specifically highlights the role of LTB4 and leukocytes in cardiovascular events. However, analysis of correlation between LT traits and coagulation factors (factors IX, VII, VIII, XI, XII and fibrinogen) and platelet function (PFA-100 CEPI-CT and CADP-CT) revealed no correlation (22).

The lack of observed correlation between investigated SNPs in the LT pathway and platelet function phenotypes or LT concentrations in our study may be explained by a limited number of investigated variants, which represent only a small fraction of all previously documented variants in LOX pathway genes. Genotyped variants were selected on the basis of previous publications concerning mainly coronary artery disease (CAD) and MI (15–20,23–25). It is possible that selected variants may be involved in atherosclerosis and the risk of MI in studied population, through indirect association with platelet reactivity and the LT pathway. Certain variants, not investigated in our cohort, may affect the metabolism of the LT pathway and thus modify platelet reactivity and increase the risk of CAD and MI. Finally, the observed nominal statistically significant results may not have achieved statistical significance using multiple comparison correction due to the fact that the number of investigated patients was too small to obtain the true statistically significant results for a smaller than initially assumed OR.

The available results from previously published studies on the effect of genetic variations of the LT pathway on CAD, MI and stroke risk are inconsistent and depend on the analyzed population (15–20,22–25). As such, in other populations, the genetic variants investigated in our study may alter the risk of thrombosis associated with platelet functions. Furthermore, only patients with T2DM were included in our study, and we do not know if the lack of effect is related to the diabetic population and may become evident in other populations (CAD and non-diabetics).

A further limitation of our study is related to the choice of tests for measuring platelet reactivity. Light transmission aggregometry (LTA) is considered to be the ‘gold standard’ of platelet function tests, but it is poorly standardized, requires a specialist laboratory and is unlikely to be used widely in routine clinical practice (26). Thus, in our study, we assessed platelet reactivity by using three point-of-care tests (CEPI-CT and CADP-CT by PFA-100 and ARU by VerifyNow aspirin assay) that are used in multiple centers.

In conclusion, the results of our study failed to confirm whether the selected variants in genes within the LT metabolism pathway contribute to platelet reactivity in a diabetic population treated with ASA.

 Acknowledgements

The authors would like to thank Thutrang Nguyen (Laboratory Manager) from the SNP Genotyping Core Facility at the Children’s Hospital, Boston, Massachusetts, USA, for performing the custom Sequenom iPLEX assay. Dr Postula was supported by a Fulbright Fellowship. The AVOCADO study was supported financially as part of the research grant from the Polish Pharmaceutical Company ADAMED for a Young Scientist 2007 Award (grant number: 1WR DAR1/2007) and the research grant of the National Centre for Science (grant number: 2011/01/N/NZ2/02987).

 References MortensenSBLarsenSBGroveELKristensenSDHvasAMReduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitusThromb Res126e318e3222010 EvangelistaVde BerardisGTotaniLPersistent platelet activation in patients with type 2 diabetes treated with low doses of aspirinJ Thromb Haemost5219722032007 DiChiaraJBlidenKPTantryUSThe effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) studyDiabetes56301430192007 Martel-PelletierJLajeunesseDReboulPPelletierJPTherapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugsAnn Rheum Dis625015092003 Peters-GoldenMHendersonWRJrLeukotrienesN Engl J Med357184118542007 JohnsonADThe genetics of common variation affecting platelet development, function and pharmaceutical targetingJ Thromb Haemost92462572011 PostulaMKaplon-CieslickaARosiakMGenetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genesJ Thromb Haemost9229123012011 NielsenHLKristensenSDThygesenSSAspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometryThromb Res1232672732008 PostulaMJanickiPKRosiakMNew single nucleotide polymorphisms associated with differences in platelets reactivity in patients with type 2 diabetes treated with acetylsalicylic acid: genome-wide association approach and pooled DNA strategyJ Thromb Thrombolysis3665732013 RendaGZurroMMalatestaGRuggieriBDe CaterinaRInconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistanceHaematologica95209521012010 RosiakMPostulaMKaplon-CieslickaAThe effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO studyKardiol Pol7165525572013 KunickiTJWilliamsSASalomonDRGenetics of platelet reactivity in normal, healthy individualsJ Thromb Haemost7211621222009 ChakrounTAddadFAbderazekFScreening for aspirin resistance in stable coronary artery patients by three different testsThromb Res1214134182007 Gonzalez-ConejeroRRiveraJCorralJAcuñaCGuerreroJAVicenteVBiological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?Stroke362762802005 ZhangKWangYYLiuQJTwo single nucleotide polymorphisms in ALOX15 are associated with risk of coronary artery disease in a Chinese Han populationHeart Vessels253683732010 ZhaoJHeZMaSLiLAssociation of ALOX15 gene polymorphism with ischemic stroke in Northern Chinese Han populationJ Mol Neurosci474584642012 HelgadottirAGretarsdottirSSt ClairDAssociation between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish populationAm J Hum Genet765055092005 HelgadottirAManolescuAHelgasonAA variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarctionNat Genet3868742006 Linsel-NitschkePGötzAMedackAGenetic variation in the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) is associated with myocardial infarction in the German populationClin Sci (Lond)1153093152008 HartialaJLiDContiDVGenetic contribution of the leukotriene pathway to coronary artery diseaseHum Genet1296176272011 WerzOSteinhilberDTherapeutic options for 5-lipoxygenase inhibitorsPharmacol Ther1127017182006 CamachoMMartinez-PerezABuilAGenetic determinants of 5-lipoxygenase pathway in a Spanish population and their relationship with cardiovascular riskAtherosclerosis2241291352012 BurdonKPRudockMELehtinenABHuman lipoxygenase pathway gene variation and association with markers of subclinical atherosclerosis in the diabetes heart studyMediators Inflamm20101701532010 CrosslinDRShahSHNelsonSCGenetic effects in the leukotriene biosynthesis pathway and association with atherosclerosisHum Genet1252172292009 GirelliDMartinelliNTrabettiEALOX5AP gene variants and risk of coronary artery disease: an angiography-based studyEur J Hum Genet159599662007 MichelsonADMethods for the measurement of platelet functionAm J Cardiol10320A26A2009

Metabolic pathways of arachidonic acid and single nucleotide polymorphisms within the leukotriene metabolic pathway provided as rs#. Gene names are provided in brackets. 5-HPETE, 5S hydroperoxyeicosatetraenoic acid; 12-HETE, 12S hydroeicosatetraenoic acid; 15-HETE, 15S hydroeicosatetraenoic acid; LT, leukotriene A4/B4/C4/D4/E4.

Demographic and clinical characteristics of the study patients (n=287).

Characteristic Result
Demographics
 Age (years) 67.6±8.7
 Female, n (%) 135 (47.5)
 BMI 31.19±12.0
 SBP (mmHg) 142.3±18.9
 DBP (mmHg) 80.5±11.3
 Dyslipidemia, n (%) 234 (82.4)
 Hypertension, n (%) 262 (92.3)
 CAD, n (%) 162 (57.0)
 Prior MI, n (%) 87 (30.6)
 Prior stroke, n (%) 23 (8.1)
 Heart failure, n (%) 107 (37.7)
 History of smoking, n (%) 160 (56.3)
 Current smoking, n (%) 28 (9.8)
Concurrent medications, n (%)
 Oral hypoglycemics 243 (85.6)
 Insulin 93 (32.7)
 β-blockers 205 (72.2)
 ACE inhibitors 185 (65.1)
 Statins 206 (72.6)
Biochemical and hematological parameters
 HGB (g/dl) 13.8±1.3
 HCT (%) 41.3±4.5
 WBC (103/mm3) 7.1±2.2
 PLT (103/mm3) 227.8±58.3
 MPV (fl) 9.9±1.2
 eGFR (ml/min/1.73) 70.8±20.9
 HbA1c (%) 7.0±1.3
 hsCRP (mg/l) 4.1±5.6
 CEPI-CT, sec (IQR) 266.5 (129)
 CADP-CT, sec (IQR) 97.0 (49)
 VerifyNow, ARU (IQR) 456.5 (97.5)
 S-TxB2, ng/ml (IQR) 0.153 (0.142)
 LTB4, pg/ml (IQR) 102.585 (51.26)
 LTE4, pg/mg creatinine (IQR) 808.915 (82.637)

Data are expressed as the mean ± SD, unless otherwise indicated. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; MI, myocardial infarction; ACE, angiotensin-converting enzyme; HGB, hemoglobin; HCT, hematocrit; WBC, white blood cells; PLT, platelet count; MPV, mean platelet volume; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated hemoglobin; hsCRP, high sensitivity C-reactive protein; CEPI-CT, collagene/epinephrine closure time; CADP-CT, collagen/adenosine diphosphate closure time; IQR, interquartile range; ARU, aspirin reaction units; S-TxB2, serum thromboxane B2; LTB4, leukotriene B4; LTE4, leukotriene E4.

Frequency of alleles and genotypes for single nucleotide polymorphisms (SNP) in the investigated group of patients.

Gene name, SNP (rs#) Allele frequency Genotype frequency HWE (P-value)
ALOX15 (rs7217186) C (0.523); T (0.477) CC (0.289); CT (0.467); TT (0.244) 0.700
ALOX15 (rs11568061) A (0.254); G (0.746) AA (0.052); AG (0.404); GG (0.544) 0.620
ALOX5AP (rs17222842) A (0.094); G (0.906) AA (0.007); AG (0.175); GG (0.818) 0.910
ALOX5AP (rs10507391) A (0.285); T (0.715) AA (0.084); AT (0.402); TT (0.514) 0.950
ALOX5AP (rs17216473) A (0.079); G (0.921) AG (0.157); GG (0.843) 0.420
LTA4H (rs61937881) C (0.792); T (0.208) CC (0.603); CT (0.362); TT (0.035) 0.120
ALOX5 (rs12221233) C (0.989); T (0.011) CC (0.977); CT (0.023) 0.980
LTA4H (rs2540475) A (0.186); G (0.814) AA (0.035); AG (0.302); GG (0.663) 1.000
ALOX12 (rs11571355) A (0.628); G (0.372) AA (0.392); AG (0.473); GG (0.135) 0.780
ALOX5 (rs2291427) A (0.272); G (0.728) AA (0.066); AG (0.411); GG (0.523) 0.710
ALOX12 (rs2292350) A (0.380); G (0.620) AA (0.143); AG (0.474); GG (0.383) 0.980
LTA4H (rs2660899) G (0.964); T (0.036) GG (0.949); GT (0.031); TT (0.020) 0.960
LTA4H (rs2660898) G (0.062); T (0.938) GT (0.124); TT (0.876) 0.056
LTA4H (rs1978331) A (0.596); G (0.404) AA (0.345); AG (0.502); GG (0.153) 0.780
LTA4H (rs6538697) C (0.074); T (0.926) CC (0.007); CT (0.135); TT (0.858) 1.000
ALOX5AP (rs4769060) A (0.542); G (0.458) AA (0.269); AG (0.546); GG (0.185) 0.990
ALOX5 (rs745986) A (0.782); G (0.218) AA (0.610); AG (0.345); GG (0.045) 0.800
LTA4H (rs2540477) A (0.780); G (0.220) AA (0.591); AG (0.377); GG (0.032) 0.650
ALOX5AP (rs9315050) A (0.966); G (0.034) AA (0.933); AG (0.063); GG (0.004) 0.690
LTA4H (rs17677715) C (0.151); T (0.849) CC (0.011); CT (0.281); TT (0.708) 0.260
ALOX5AP (rs9551963) A (0.489); C (0.511) AA (0.238); AC (0.545); CC (0.217) 0.930
ALOX12 (rs2271316) C (0.418); G (0.582) CC (0.226); CG (0.383); GG (0.391) 0.140
LTA4H (rs2540482) C (0.240); T (0.760) CC (0.043); CT (0.394); TT (0.563) 0.660

HWE, Hardy-Weinberg equilibrium.

Effect of various analyzed SNP genotypes in the LT pathway on platelet reactivity, LTB4 plasma levels and the urine excretion of LTE4 in diabetic patients on ASA therapy.

Analyzed SNPs in LT pathway VerifyNow (ARU) CEPI-CT (sec) CADP-CT (sec) LTB4 (pg/ml) LTE4 (pg/ml Cr)
rs7217186 C>T
 Homozygotes for major allele (n=83) 468.5 (88) 233.5 (134) 92.0 (54) 102.590 (48.1) 786.470 (665.7)
 Heterozygotes (n=134) 456.0 (88) 261.0 (136) 99.0 (46) 103.090 (61.9) 823.535 (721.9)
 Homozygotes for minor (variant) allele (n=70) 466.0 (103) 285.0 (126) 64.0 (51) 110.655 (67.3) 935.800 (935.9)
 P-value (KW test) 0.736 0.500 0.397 0.533 0.949
rs11568061 G>A
 Homozygotes for major allele (n=156) 466.5 (99) 273.5 (128) 100.5 (60) 109.250 (69.2) 781.230 (774.9)
 Heterozygotes (n=116) 454.0 (90) 234.0 (136) 95.0 (39) 96.500 (43.5) 786.470 (593.1)
 Homozygotes for minor (variant) allele (n=15) 460.0 (92) 273.5 (161) 99.5 (37) 112.730 (78.6) 1011.700 (663.7)
 aP-value (KW test) 0.597 0.870 0.326 0.107 0.278
rs17222842 G>A
 Homozygotes for major allele (n=234) 457.0 (93) 265.0 (132) 97.0 (46) 105.830 (53.6) 843.410(728.5)
 Heterozygotes (n=50) 457.0 (122) 268.0 (101) 107.0 (66) 102.590 (50.0) 641.650 (536.5)
 Homozygotes for minor (variant) allele (n=2) 492.5 (-) 132.5 (-) 82.0 (-) 91.055 (-) 1313.435 (-)
 aP-value (KW test) 0.633 0.168 0.424 0.983 0.113
rs10507391 T>A
 Homozygotes for major allele (n=147) 454.0 (83) 247.5 (133) 96.0 (42) 107.005 (57.2) 834.115 (725.3)
 Heterozygotes (n=115) 456.5 (117) 287.5 (124) 99.0 (56) 102.615 (61.3) 770.225 (809.5)
 Homozygotes for minor (variant) allele (n=24) 484.0 (104) 285.0 (138) 95.0 (74) 93.410 (43.3) 787.125 (466.0)
 aP-value (KW test) 0.307 0.227 0.529 0.167 0.706
rs17216473 G>A
 Homozygotes for major allele (n=220) 456.0 (97) 266.5 (132) 97.0 (45) 107.150 (58.1) 834.930 (742.6)
 Heterozygotes (n=41) 450.5 (100) 236.0 (148) 95.5 (50) 97.635 (49.3) 689.775 (781.5)
 Homozygotes for minor (variant) allele (n=0) n/a n/a n/a n/a n/a
 P-value (MW) test) 0.568 0.574 0.921 0.687 0.131
rs61937881 C>T
 Homozygotes for major allele (n=173) 461.5 (97) 231.5 (138) 96.0 (48) 103.520 (69.4) 879.390 (754.5)
 Heterozygotes (n=104) 450.0 (96) 295.0 (107) 99.0 (47) 106.090 (52.6) 762.500 (578.2)
 Homozygotes for minor (variant) allele (n=10) 414.0 (94) 188.0 (166) 143.0 (210) 93.130 (66.3) 598.230 (982.5)
 aP-value (KW test) 0.336 0.044 0.442 0.637 0.277
rs12221233 C>T
 Homozygotes for major allele (n=255) 456.5 (99) 272.5 (130) 97.0 (48) 105.770 (51.3) 809.060 (720.7)
 Heterozygotes (n=6) 425.0 (65) 235.5 (195) 116.0 (79) 96.660 (87.5) 876.920 (655.2)
 Homozygotes for minor (variant) allele (n=0) n/a n/a n/a n/a n/a
 P-value (MW test) 0.267 0.666 0.358 0.502 0.696
rs2540475 G>A
 Homozygotes for major allele (n=189) 465.0 (94) 241.0 (136) 96.0 (45) 106.020 (53.5) 843.410 (738.2)
 Heterozygotes (n=86) 445.0 (82) 300.0 (126) 99.5 (63) 97.255 (50.3) 774.980 (747.3)
 Homozygotes for minor (variant) allele (n=10) 436.0 (116) 188.0 (146) 100.0 (210) 93.550 (78.6) 739.935 (575.4)
 aP-value (KW test) 0.248 0.258 0.611 0.816 0.785
rs11571355 A>G
 Homozygotes for major allele (n=110) 465.0 (92) 285.0 (128) 95.0 (50) 102.585 (46.2) 812.600 (799.4)
 Heterozygotes (n=133) 450.0 (104) 241.0 (130) 100.0 (47) 105.020 (55.2) 786.470 (770.7)
 Homozygotes for minor (variant) allele (n=38) 459.0 (113) 265.0 (141) 97.0 (63) 116.080 (65.3) 781.230 (500.5)
 aP-value (KW test) 0.856 0.506 0.639 0.731 0.871
rs2291427 G>A
 Homozygotes for major allele (n=150) 457.0 (93) 247.0 (138) 97.0 (45) 102.990 (48.0) 833.300 (694.8)
 Heterozygotes (n=118) 462.5 (104) 268.5 (124) 99.0 (59) 104.725 (68.9) 760.455 (770.5)
 Homozygotes for minor (variant) allele (n=19) 455.0 (65) 288.0 (129) 95.0 (34) 87.585 (54.6) 850.995 (934.9)
 aP-value (KW test) 0.308 0.187 0.912 0.327 0.657
rs2292350 G>A
 Homozygotes for major allele (n=110) 465.0 (94) 285.0 (125) 96.5 (46) 102.590 (46.8) 808.770 (775.9)
 Heterozygotes (n=136) 455.5 (98) 240.5 (134) 98.5 (49) 103.260 (54.8) 839.170 (730.8)
 Homozygotes for minor (variant) allele (n=41) 451.5 (113) 258.5 (140) 97.0 (65) 117.490 (66.7) 761.550 (520.4)
 aP-value (KW test) 0.764 0.229 0.719 0.845 0.650
rs2660899 G>T
 Homozygotes for major allele (n=187) 456.0 (96) 263.0 (135) 99.0 (50) 103.255(47.8) 812.600 (758.6)
 Heterozygotes (n=6) 457.0 (97) 267.0 (129) 97.0 (49) 114.000 (52.0) 910.000 (790.0)
 Homozygotes for minor (variant) allele (n=4) 493.5 (178) 264.5 (105) 108.0 (94) 113.230 (214.9) 1311.170 (995.9)
 aP-value (MW test) 0.260 0.810 0.890 0.132 0.728
rs2660898 T>G
 Homozygotes for major allele (n=127) 458.5 (99) 236.0 (132) 96.0 (44) 104.275 (65.4) 870.515 (796.2)
 Heterozygotes (n=18) 439.5 (87) 187.5 (144) 103.5 (222) 97.255 (55.0) 681.855 (932.5)
 Homozygotes for minor (variant) allele (n=0) n/a n/a n/a n/a n/a
 P-value (MW test) 0.160 0.909 0.426 0.499 0.327
rs1978331 A>G
 Homozygotes for major allele (n=99) 460.0 (98) 238.0 (146) 95.0 (45) 105.020 (66.3) 793.150 (794.4)
 Heterozygotes (n=144) 456.0 (96) 274.0 (129) 99.0 (52) 106.020 (54.8) 809.060 (563.6)
 Homozygotes for minor (variant) allele (n=44) 443.0 (92) 262.5 (133) 98.5 (69) 105.800 (55.4) 759.810 (668.2)
 aP-value (KW test) 0.620 0.657 0.687 0.501 0.598
rs6538697 T>C
 Homozygotes for major allele (n=242) 456.0 (98) 273.0 (127) 98.0 (46) 106.090 (52.1) 784.480 (758.8)
 Heterozygotes (n=38) 467.5 (72) 189.0 (137) 104.0 (171) 98.100 (85.4) 897.415 (598.5)
 Homozygotes for minor (variant) allele (n=2) 403.5 (-) 232.0 (-) 83.5 (-) 319.595 (-) 1725.750 (-)
 P-value (MW test) 0.520 0.159 0.937 0.911 0.765
rs4769060 A>G
 Homozygotes for major allele (n=70) 481.0 (115) 247.0 (148) 95.0 (62) 103.520 (52.2) 808.770 (723.5)
 Heterozygotes (n=142) 459.5 (95) 266.5 (126) 99.0 (48) 107.735 (48.9) 821.180 (733.5)
 Homozygotes for minor (variant) allele (n=48) 446.0 (64) 277.0 (155) 95.5 (51) 98.960 (81.7) 715.380 (679.5)
 aP-value (KW test) 0.460 0.692 0.815 0.477 0.828
rs745986 A>G
 Homozygotes for major allele (n=175) 456.0 (93) 247.0 (137) 97.0 (52) 105.803 (54.2) 793.150 (705.4)
 Heterozygotes (n=99) 469.0 (123) 283.0 (114) 97.0 (42) 102.590 (54.4) 771.370 (829.6)
 Homozygotes for minor (variant) allele (n=13) 426.5 (30) 272.5 (166) 102.0 (107) 130.625 (61.8) 888.695 (309.1)
 aP-value (KW test) 0.027 0.560 0.988 0.553 0.852
rs2540477 A>G
 Homozygotes for major allele (n=168) 456.0 (93) 277.0 (130) 101.5 (56) 105.120 (49.0) 797.765 (660.5)
 Heterozygotes (n=107) 459.0 (100) 226.0 (140) 91.0 (45) 105.770 (63.8) 808.770 (761.8)
 Homozygotes for minor (variant) allele (n=9) 457.5 (153) 294.0 (51) 99.0 (46) 107.285 (51.1) 691.830 (833.3)
 aP-value (KW test) 0.492 0.212 0.117 0.929 0.636
rs9315050 A>G
 Homozygotes for major allele (n=266) 458.5 (96) 257.5 (134) 97.0 (49) 105.395 (56.3) 789.810 (740.5)
 Heterozygotes (n=18) 459.5 (74) 300.0 (67) 101.0 (79) 108.940 (45.8) 888.530 (568.5)
 Homozygotes for minor (variant) allele (n=1) n/a n/a n/a n/a n/a
 P-value (MW test) 0.690 0.184 0.248 0.486 0.243
rs17677715 T>C
 Homozygotes for major allele (n=199) 461.5 (98) 243.5 (135) 96.5 (49) 105.425 (70.4) 7850.460 (752.0)
 Heterozygotes (n=79) 447.0 (95) 296.0 (126) 99.0 (42) 109.250 (45.5) 741.870 (567.2)
 Homozygotes for minor (variant) allele (n=3) 414.0 (-) 188.0 (-) 298.0 (-) 93.130 (-) 525.330 (-)
 P-value (MW test) 0.133 0.093 0.500 0.073 0.508
rs9551963 C>A
 Homozygotes for major allele (n=60) 476.0 (118) 222.5 (148) 96.0 (55) 104.645 (52.1) 850.995 (861.5)
 Heterozygotes (n=151) 465.0 (93) 265.0 (125) 100.0 (47) 107.150 (53.6) 786.470 (731.3)
 Homozygotes for minor (variant) allele (n=66) 444.0 (57) 280.0 (139) 96.5 (51) 98.960 (61.1) 760.085 (719.6)
 aP-value (KW test) 0.747 0.639 0.562 0.342 0.809
rs2271316 G>C
 Homozygotes for major allele (n=100) 446.0 (97) 266.5 (127) 97.0 (57) 106.135 (48.9) 814.040 (727.1)
 Heterozygotes (n=98) 462.5 (87) 264.0 (136) 98.5 (39) 101.070 (61.3) 749.560 (698.2)
 Homozygotes for minor (variant) allele (n=58) 481.0 (110) 238.0 (128) 99.0 (54) 105.830 (62.1) 784.480 (814.0)
 aP-value (KW test) 0.468 0.664 0.897 0.855 0.893
rs2540482 T>C
 Homozygotes for major allele (n=156) 455.0 (94) 265.0 (134) 100.0 (61) 104.410 (48.3) 786.470 (662.7)
 Heterozygotes (n=109) 459.0 (95) 230.0 (135) 95.0 (40) 103.530 (63.4) 808.340 (730.5)
 Homozygotes for minor (variant) allele (n=12) 457.5 (163) 280.0 (73) 99.0 (50) 110.665 (67.3) 945.800 (935.9)
 aP-value (KW test) 0.448 0.626 0.199 0.650 0.637

Data are presented as the median and the interquartile range (IQR).

P-value calculated using the Kruskall Wallis (KW) test for differences between three analyzed genotypes for each SNP.

ASA, acetylsalicylic acid; n, number of carriers for each genotype; MAF, minor allele frequency for each analyzed SNP in investigated cohort; ARU, aspirin reaction unit; CEPI-CT, collagen/epinephrine closure time; CADP-CT, collagen/adenosine diphosphate closure time; LTB4, leukotriene B4; LTE4, leukotriene E4.